Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

0301 basic medicine Cancer Research Consensus Monitoring International Cooperation Immunology Tregs Cell Separation Lymphocyte Activation T-Lymphocytes, Regulatory RC0254 03 medical and health sciences Antigens, CD Monitoring, Immunologic Immunology and Allergy Animals Humans Flow cytometry Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences Cells, Cultured Ovarian Neoplasms Forkhead Transcription Factors Reference Standards Flow Cytometry R1 3. Good health Ki-67 Antigen Oncology Phenotyping QR180 Original Article Female Tumor Escape Biomarkers
DOI: 10.1007/s00262-015-1729-x Publication Date: 2015-06-27T17:24:56Z
ABSTRACT
Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and (b) the gating strategy required to define human Tregs in this context, making it difficult to draw final conclusions. Therefore, we have organized an international workshop on the detection and functional testing of Tregs with leading experts in the field, and 40 participants discussing different analyses and the importance of different markers and context in which Tregs were analyzed. This resulted in a rationally composed ranking list of "Treg markers". Subsequently, the proposed Treg markers were tested to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues. Here, we conclude that the CD3, CD4, CD25, CD127, and FoxP3 markers are the minimally required markers to define human Treg cells. Staining for Ki67 and CD45RA showed to provide additional information on the activation status of Tregs. The use of markers was validated in a series of PBMC from healthy donors and cancer patients, as well as in tumor-draining lymph nodes and freshly isolated tumors. In conclusion, we propose an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the context-dependent analysis of Tregs by flow cytometry.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (54)
CITATIONS (166)